Supramolecular polymers have a practical impact on the healthcare field as they can act as scaffolds to repair parts of organs such as the brain or heart. In addition, they can provide insight into theories relating to the origins of life. For instance, the hypothesis that RNA played a more important role in early biology, the RNA World hypothesis, would be strengthened if there were a way to show the spontaneous formation of RNA-like polymers from monomer units. However, the natural nucleobases do not assemble at the monomer level, nor do they form nucleosides readily with ribose, leading some to speculate that the first nucleobases may have been different from the ones used in biology today. This conundrum encouraged us to begin looking for alternative nucleobases that are able to self-assemble into polymers capable of storing information. Our lab has recently demonstrated that a modified 2,4,6-triaminopyrimidine (TAP) will assemble with cyanuric acid (CA) in water through interactions that are analogous to those between complementary nucleobases found in DNA and RNA. When TAP is modified at one of its three faces, it can pair through specific hydrogen bonding with CA on two of its faces, forming rosette structures. These rosettes self-assemble to form extremely long structures through the stacking of tens of thousands of rosettes. In this study we are investigating prebiotically relevant syntheses of TAP nucleosides. Using chromatography techniques and nuclear magnetic resonance we found that the unmodified TAP with D-ribose formed nucleosides in 60% yields with the major product (20%) being a C-nucleoside 5-β-ribofuranosyl-2,4,6-triaminoprymidine or TARC. TARC forms hydrogels with CA, both in the crude reaction and after purification, indicative of the formation of supramolecular polymers out of a complex mixture. The results of this study provide support for the possibility of pre-RNA molecules.

Nucleoside polyphosphates and their conjugates, such as nucleoside triphosphates, nucleoside tetraphosphates, sugar nucleotides, dinucleoside pyro- and higher order polyphosphates, 2’,3’-cyclic nucleoside monophosphates, and 2´-deoxynucleoside-5´-tetraphosphates in which a fluorescent label is attached to the terminal phosphate have many biological roles and have been developed into drugs. However, their synthesis remains a challenge. Several novel and efficient approaches to the synthesis of nucleoside polyphosphates and their conjugates were developed. In the first approach dinucleoside polyphosphates (NpnN’s where n = 2-4) are prepared via in situ trifluoroacetate protection and imidazolium activation of nucleoside 5’-monophosphates. This methodology was also used to prepare a substrate-intermediate analog of the reaction catalyzed by cytidine triphosphate synthase (CTPS) a recognized target for the development of antineoplastic, antiviral and antiprotozoal agents. The second approach uses sulfonylimidazolium salts as key reagents for generating highly reactive nucleotide donors. The procedure is rapid, produces a wide variety of nucleoside polyphosphates and their conjugates in high yield, does not require protection and subsequent deprotection of the nucleotide donors or acceptors and can be used to activate nucleoside mono-, di-, and triphosphates and a wide variety of acceptors. Finally an entirely new approach to the synthesis of nucleoside tetraphosphates (Np4’s), dinucleoside pentaphosphates (Np5N’s) and nucleoside tetraphosphates in which a fluorescent dye is attached to the terminal phosphate is described employing an activated form of cyclic trimetaphosphate as a novel phosphorylating agent. Attempts to prepare nucleoside triphosphates by subjecting unprotected ribonucleosides and 2’-deoxyribonucleosides to activated cyclic trimetaphosphate failed. Instead nucleoside 2’,3’-cyclic phosphates were obtained in good yield with the ribonucleoside substrates. This represents a new and convenient approach to the synthesis of this class of compounds.

Chemical modifications of oligonucleotides provide an important tool to understand how the natural substrate works as well as how to improve their biochemical and biological properties as potential therapeutics and diagnostics. Our carba-LNA (2',4'-carba-bridged Locked Nucleic Acid) modified oligo-DNA or -RNA have been found to be useful to modulate oligo-RNA and -DNA activity. This thesis is based on four papers: Paper I (J. Org. Chem. 2010, 75, 7112-7128) deals with the synthesis of 2',4'-propylene-bridged (Carba-ENA) thymidine and its analogues. These carba-ENA nucleosides have been subsequently incorporated into 15mer antisense oligodeoxynucleotides (AON), and their affinity toward complementary mRNA and DNA, as well as their nuclease resistance and RNase H recruitment capability have been investigated in comparison with those of the native and ENA counterparts. Paper II (J. Org. Chem. 2012, 77, 6855–6872) illustrates the synthesis of dimethylbicyclo[2.2.1]heptane and a diastereomeric mixture of oxabicyclo[2.2.1]heptanes by the free-radical ring-closure reaction approach. The role of steric factors for different chair- and the boat-like transition states was evaluated involving the 5-exo radical ring closure reaction to a tethered olefin. Paper III (J. Org. Chem. 2012, 77, 9747-9755) shows an unusual strain releasing reaction of 1-mesyloxy-8,7-dimethylbicyclo[2.2.1]heptane by a base-promoted substitution at the chiral C3 followed by spontaneous concerted ring opening involving the most strained C2-C3-C4 bonds (with bond angle 94°) and the C2 bridgehead leading to anti-endo elimination of the C1-mesyloxy group by the conjugate base of adenine or thymine to give two diastereomeric C3'(S) and C3'(R) derivatives of 1-thyminyl and 9-adeninyl cyclohexene, and a mechanistic rational has been formulated. Paper IV (J. Org. Chem. 2014, 79, 7266−7276) focuses on the diastereospecific synthesis of E/Z bicyclo[2.2.1]heptane-7- and oxabicyclo[2.2.1]heptane-8-oximes and their corresponding C-nitroso derivatives. The comparative kinetic and thermodynamic studies of the conversions of the C-nitroso side products to the required oximes have been delineated leading to the synthesis of desmethyl sugar derivatives.

A identificação de genes relacionados com resistência a compostos antiparasitários tem contribuído para um melhor entendimento do mecanismo de ação de alguns desses compostos. Utilizando a estratégia que permite a indução de super-expressão após transfecção gênica, isolamos dois loci relacionados com resistência ao análogo tóxico de purina, tubercidina (TUB). Em um desses locus identificamos um ortólogo do gene TOR (TOxic nucleoside Resistance) em L. (L.) major (TOR-Lm), capaz de conferir altos níveis de resistência a TUB. A identificação e localização cromossomal do segundo locus foi obtida, mas os testes funcionais em presença de TUB não foram tão significativos quanto os obtidos após a transfecção do TOR-Lm. Na segunda parte desta dissertação avaliamos a eficácia da associação de TUB com um inibidor específico do transporte de nucleosídeos em mamíferos, nitrobenziltioinosina (NBMPR), visando reverter a toxicidade de TUB apenas no hospedeiro. Demonstramos que TUB tem uma potente ação anti-parasitária em culturas de Leishmania spp., e que o inibidor NBMPR é capaz de proteger células mamíferas de camundongos infectados da ação tóxica de TUB. / Gene identification associated with drug resistance has contributed to a better understanding of the mechanism of action of anti parasitic compounds. Using transfection and over-expression selection strategy we isolated two loci related with the resistance of tubercidin (TUB), a toxic analog purine. In the first locus we identified an ortholog of the TOR gene (TOxic nucleoside Resistance) in L. (L.) major (TOR-Lm), capable to render wild cells resistance to TUB after transfection and over-expression. Chromosomal location and identification of the second locus was done, but functional tests in the presence of TUB were not as significant as those obtained after TOR-Lm transfection. In the second part of this work, we evaluate the effectiveness of the association of TUB with an inhibitor specific to the mammals nucleoside transport, as nitrobenzylthioinosine (NBMPR), aimed at reversing the TUB toxicity only on the host. We first demonstrate that TUB has a potent anti-parasitic action in cultures of Leishmania spp. Then, we discuss the capacity of the NBMPR inhibitor to protect infected macrophages from the toxic effects of TUB.

Gold(I)phosphines, nucleoside analogues, and azole derivatives have been identified as promising anticancer compounds. The clinical use of these individual compounds is, however, limited due to non-selectivity associated with adverse effects and developed resistance. This study investigated seven novel gold compounds that contain either a nucleoside analogue or an azole, bound via a gold nitrogen bond, which have been designed and synthesized by Dr. Horvath under the supervision of Prof. Raubenheimer from the University of Stellenbosch. The novel compounds are divided into purinecontaining/ nucleoside analogue compounds (UH 86.2, UH 75.1, UH 58.1, UH 145.1) and azole-containing compounds (UH 107.1, UH 126.1, UH 127.1). The anticancer effects of these novel compounds were compared with that of previously described anticancer compounds [Au(dppe)2]Cl and cisplatin. The octanol/water partition coefficients (PC) of the compounds were measured in order to determine whether a correlation between the lipophilicity of the structures and the cytotoxic potency and selectivity exists. This might provide further insight for structural alterations of the compounds in order to improve their anticancer activity. The results from octanol/water PC determinations, revealed that the purine-containing compounds (UH 86.2, UH 75.1, UH 58.1, and UH 145.1), as well as the azole-containing compound, UH 127.1, exhibited hydrophilic properties, while the azole-containing compounds, UH 107.1 and UH 126.1 are lipophilic. In contrast to results by Berners-Price et al. (1999), that reported a direct proportionality between lipophilicity and cytotoxicity, for the current study, involving HeLa cells, CoLo cells, normal resting and PHA stimulated lymphocytes, no correlation was observed. For the Jurkat cell line, however, an increase in lipophilicity for the series of compounds studied was accompanied by an increase in cytotoxicity. The reason for the exception is not yet fully understood. The in vitro tumour specificity of each compound was established with cytotoxicity assays on various cancer cell lines and normal cell cultures. The cancer cell lines included human cervical cancer (HeLa) cells, human colon cancer (CoLo) cells, and human lymphocytic leukaemia (Jurkat) cells. The normal cell cultures included human resting lymphocytes and human phytohemaglutin (PHA) stimulated lymphocytes. From this data, the four most promising novel compounds were identified. Additional tests were performed by adding these four compounds to cancer cells including human breast cancer (MCF-7) cells, and cisplatin sensitive and resistant human ovarian cancer (A2780 and A2780cis) cells as well as normal chicken embryo fibroblasts. The tumour specificity of each compound was determined from the results obtained via the cytotoxicity assays. The compound is more selective the higher the tumour specificity. Cisplatin exhibited the highest tumour specificity, and [Au(dppe)2]Cl, the lowest. The two most promising novelcompounds were identified as UH 126.1 and UH 127.1, which was evidenced by their high tumour specificities. Further experiments were conducted with these two azolecontaining compounds by using Jurkat cells. The possible mechanism by which the novel compounds induce cytotoxicity was investigated with flow cytometric analysis. The effects of the compounds on the cell death pathway, the mitochondrial membrane potential and the cell cycle were determined. These results indicated that the novel compounds, UH 126.1 and UH 127.1 initiate the apoptotic cell death pathway rather than the necrotic cell death pathway. According to results, UH 126.1 and UH 127.1 influenced the status of the mitochondrial membrane potential (MMP) non-selectively and only at high concentrations. Although involvement of mitochondria in the mechanism of action cannot be excluded, results indicated that it is most likely not the primary target. After investigating the effects of the two novel azole-containing compounds on the cell cycle in Jurkat cells, it was detected that these compounds induce cell accumulation in the G1 phase of the cell cycle. It was concluded that UH 126.1 and UH 127.1 might interfere with the cell cycle indirectly, possibly by inhibition of cyclin-dependent kinases and/or other enzymes necessary for DNA replication. In an acute in vivo toxicity test during this study, results revealed drug induced adverse effects (such as significant weight loss, piloerection and diarrhoea), in the mice that received 3 and 6ìmol/kg of both UH 126.1 and UH 127.1. Evidence also revealed signs of nephrotoxicity and epatotoxicity. Due to minimal adverse effects observed in the groups that received UH 126.1 and UH 127.1 at the concentration of 1,5ìmol/kg, this is the suggested maximum tolerated dose (MTD) for these compounds. Further dose-range studies with UH 126.1 and UH 127.1 are, however, needed in order to evaluate clinicalefficacy. Copyright / Dissertation (MSc)--University of Pretoria, 2009. / Pharmacology / unrestricted

The incidence of cancer worldwide has increased over the years, and gastrointestinal cancers (G.I.) are amongst the most common forms of cancer. Nevertheless, there is still no curative treatments for this group of tumors. Nucleoside analogues are widely used in cancer treatment. The prevailing compounds are Gemcitabine (used for pancreatic cancer and other carcinomas), 5-Fluorouracil (used in breast, colon, and other cancers), Cytarabine and Clofarabine (used in leukemias). Gemcitabine, the current standard of care for various forms of solid tumors, has a limited efficacy against pancreatic cancer. The objective of this project was the development of effective drugs against pancreatic cancer. We focused on a novel class of nucleoside analogues designed to bypass the most common cellular road blocks and resistance mechanisms. After an extensive screen for cell killing activity, two lead molecules were exclusively studied: LCB2151 and LCB2132. These two molecules showed high efficacy in killing human cancer cells from three different human G.I. cell lines: BxPC3 and Capan-2, two pancreatic cell lines representative of K-Ras positive and negative tumors, as well as the liver cell line HepG2. LCB2151 showed high efficacy in killing Gemcitabine-resistant cancer cells, and a low toxicity in normal cells. Interestingly, results show that these prodrugs can efficiently bypass key resistance mechanisms developed by cancer cells. The results obtained in this project are promising and could pave the way for a more effective treatment of pancreatic cancer.

Background: Peroxisome proliferator-activated receptor δ (PPARδ) is a versatile regulator of distinct biological processes and overexpression of PPARδ in cancer may be partially related to its suppression of its own co-regulators. Aims: To determine whether recruited suppressor proteins bind to and regulate PPARδ expression, activity and PPARδ-dependent cholangiocarcinoma proliferation. Methods: Yeast two-hybrid assays were done using murine PPARδ as bait. PPARδ mRNA expression was determined by qPCR. Protein expression was measured by western blot. Immunohistochemistry and fluorescence microscopy were used to determine PPARδ expression and co-localization with NDP Kinase alpha (NM23-H2). Cell proliferation assays were performed to determine cell numbers. Results: Yeast two-hybrid screening identified NM23-H2 as a PPARδ binding protein and their interaction was confirmed. Overexpressed PPARδ or treatment with the agonist GW501516 resulted in increased cell proliferation. NM23-H2 siRNA activated PPARδ luciferase promoter activity, upregulated PPARδ RNA and protein expression and increased GW501516-stimulated CCA growth. Overexpression of NM23-H2 inhibited PPARδ luciferase promoter activity, downregulated PPARδ expression and AKT phosphorylation and reduced GW501516-stimulated CCA growth. Conclusions: We report the novel association of NM23-H2 with PPARδ and the negative regulation of PPARδ expression by NM23-H2 binding to the C-terminal region of PPARδ. These findings provide evidence that the metastasis suppressor NM23-H2 is involved in the regulation of PPARδ-mediated proliferation.

In chapter 1, we describe development of a mild and efficient method for SNAr iodination of 6-chloropurine 2'-deoxynucleosides and nucleosides. Our studies demonstrate that 6-iodopurine nucleosides are excellent substrates for certain transition metal-catalyzed cross-coupling reactions. In chapter 2, we describe synthesis of protected 6-fluoro, 6-chloro, 6-bromo and 6-sulfonylpurine nucleosides. Comparisons among 6-fluoro-, 6-chloro-, 6-bromo, 6-iodo and 6-sulfonylpurine nucleosides for SNAr reactions with various N, O and S nucleophiles were investigated. Our results demonstrate that the 6-fluoropurine nucleoside is the best substrate for SNAr reactions among the four 6-halopurine nucleosides with oxygen, sulfur and aliphatic amine nucleophiles, and also with an aromatic amine plus TFA as a catalyst. However, the 6-iodopurine nucleoside is the best substrate for the aromatic amine without acid. With oxygen and sulfur nucleophiles, the 6-sulfonylpurine nucleoside reacted even faster than the 6-fluoropurine nucleoside. In chapters 3 and 4, nickel- and palladium-based systems with imidazolium-carbene ligands can catalyze efficient Suzuki cross-couplings of arylboronic acids and 6-[(imidazol-1-yl)-, (1,2,4-trizaol-4-yl), fluoro, alkylsulfanyl and alkylsulfonyl]purine 2'-deoxynucleosides and nucleosides to give the corresponding 6-arylpurine products.

3'-Carboxymethyl-3'-deoxyadenosine derivatives were prepared from 2'-O-TBDMS-3'-deoxy-3'-[(ethoxycarbonyl)methyl]adenosine (1) via simple and efficient procedures. Conversion of 1 to 5'-azido-2'-O-TBDMS-3', 5'-dideoxy -3'-[(ethoxycarbonyl) methyl] adenosine (4) was accomplished via a novel one-pot method employing 5'-activation (TosCl) followed by efficient nucleophilic displacement with tetramethylguanidinium azide. Compound 4 was converted to a 5'-[(N-methylcarbamoyl)amino] derivative (5) via one-pot reduction/acylation employing H2/Pd-C followed by treatment with p-nitrophenyl N-methylcarbamate. The latter step of this two-step process required an efficient source of p-nitrophenyl N-methylcarbamate, thus a highly efficient new method for preparing p-nitrophenyl N-alkylcarbamate was developed. N6-phenylcarbamoyl groups were introduced by treatment with phenylisocyanate, and an efficient new method for lactonization of 2'-O-TBDMS-3'-deoxy-3'-[(ethoxycarbonyl)methyl]adenosines to give corresponding 2', 3'-lactones was also developed. Target compounds were evaluated for anti-HIV and anti-HIV integrase activities, but were not active at the concentrations tested.

No description available.